181 related articles for article (PubMed ID: 19836386)
1. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.
Rojas C; Thomas AG; Alt J; Stathis M; Zhang J; Rubenstein EB; Sebastiani S; Cantoreggi S; Slusher BS
Eur J Pharmacol; 2010 Jan; 626(2-3):193-9. PubMed ID: 19836386
[TBL] [Abstract][Full Text] [Related]
2. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
Rojas C; Stathis M; Thomas AG; Massuda EB; Alt J; Zhang J; Rubenstein E; Sebastiani S; Cantoreggi S; Snyder SH; Slusher B
Anesth Analg; 2008 Aug; 107(2):469-78. PubMed ID: 18633025
[TBL] [Abstract][Full Text] [Related]
3. Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.
Hothersall JD; Moffat C; Connolly CN
Br J Pharmacol; 2013 Jul; 169(6):1252-62. PubMed ID: 23581504
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.
Stathis M; Pietra C; Rojas C; Slusher BS
Eur J Pharmacol; 2012 Aug; 689(1-3):25-30. PubMed ID: 22683863
[TBL] [Abstract][Full Text] [Related]
5. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Navari RM
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting.
Rojas C; Slusher BS
Eur J Pharmacol; 2012 Jun; 684(1-3):1-7. PubMed ID: 22425650
[TBL] [Abstract][Full Text] [Related]
8. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann C; Herrstedt J
Expert Rev Anticancer Ther; 2010 Feb; 10(2):137-48. PubMed ID: 20131990
[TBL] [Abstract][Full Text] [Related]
9. Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.
Thomas AG; Stathis M; Rojas C; Slusher BS
Exp Brain Res; 2014 Aug; 232(8):2637-44. PubMed ID: 24969614
[TBL] [Abstract][Full Text] [Related]
10. Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.
Lummis SC; Thompson AJ
Neuropharmacology; 2013 Oct; 73():241-6. PubMed ID: 23747573
[TBL] [Abstract][Full Text] [Related]
11. Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
Del Cadia M; De Rienzo F; Weston DA; Thompson AJ; Menziani MC; Lummis SC
Bioorg Med Chem; 2013 Dec; 21(23):7523-8. PubMed ID: 24128813
[TBL] [Abstract][Full Text] [Related]
12. Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT3 receptors.
Moura Barbosa AJ; De Rienzo F; Ramos MJ; Menziani MC
Eur J Med Chem; 2010 Nov; 45(11):4746-60. PubMed ID: 20724042
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
Rojas C; Raje M; Tsukamoto T; Slusher BS
Eur J Pharmacol; 2014 Jan; 722():26-37. PubMed ID: 24184669
[TBL] [Abstract][Full Text] [Related]
14. Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
Darmani NA; Zhong W; Chebolu S; Vaezi M; Alkam T
Eur J Pharmacol; 2014 Jan; 722():2-12. PubMed ID: 24513517
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Pharmacological Evaluation of [
Mu L; Müller Herde A; Rüefli PM; Sladojevich F; Milicevic Sephton S; Krämer SD; Thompson AJ; Schibli R; Ametamey SM; Lochner M
ACS Chem Neurosci; 2016 Nov; 7(11):1552-1564. PubMed ID: 27571447
[TBL] [Abstract][Full Text] [Related]
16. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
[TBL] [Abstract][Full Text] [Related]
17. Palonosetron-5-HT
Price KL; Lillestol RK; Ulens C; Lummis SC
ACS Chem Neurosci; 2016 Dec; 7(12):1641-1646. PubMed ID: 27656911
[TBL] [Abstract][Full Text] [Related]
18. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
Constenla M
Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
[TBL] [Abstract][Full Text] [Related]
19. Allosteric modulation of 5-HT3 serotonin receptors.
Maksay G; Bíró T; Bugovics G
Eur J Pharmacol; 2005 May; 514(1):17-24. PubMed ID: 15878320
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
Shah AK; Hunt TL; Gallagher SC; Cullen MT
Curr Med Res Opin; 2005 Apr; 21(4):595-601. PubMed ID: 15899109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
